Title : A safe lithium mimetic for bipolar disorder
Authors : Singh,N., Halliday, A.C., Thomas, J.M., et al.
Journal : Nature Communications
Publication Date : 2013
Citation : Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332.
Direct Link : "http://www.nature.com/ncomms/journal/v4/n1/full/ncomms2320.html" (doi:10.1038/ncomms2320)
Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects. It is likely that a small molecule could be found with lithium-like efficacy but without toxicity through target-based drug discovery; however, therapeutic target of lithium remains equivocal. Inositol monophosphatase is a possible target but no bioavailable inhibitors exist. Here we report that the antioxidant ebselen inhibits inositol monophosphatase and induces lithium-like effects on mouse behaviour, which are reversed with inositol, consistent with a mechanism involving inhibition of inositol recycling. Ebselen is part of the National Institutes of Health Clinical Collection, a chemical library of bioavailable drugs considered clinically safe but without proven use. Therefore, ebselen represents a lithium mimetic with the potential both to validate inositol monophosphatase inhibition as a treatment for bipolar disorder and to serve as a treatment itself.
Masters DegreesSearch For Masters Degrees
An active and supportive community.
Support and advice from your peers.
Your postgraduate questions answered.
Use your experience to help others.
Enter your email address below to get started with your forum account
Enter your username below to login to your account
An email has been sent to your email account along with instructions on how to reset your password. If you do not recieve your email, or have any futher problems accessing your account, then please contact our customer support.
or continue as guest